Large Outflow of Money Witnessed in Grifols, S.A.

Grifols, S.A. (GRFS) surged 1.24% during the last session. The last traded price was up 0.21 points at $17.21. The data for the fund flow suggests that the net intraday money flow was $(-15.91) million. The fund value in upticks was recorded to be $1.51 million and in downticks, it was found to be $17.42 million. The up/down ratio for the day was measured to be 0.09. For the week, the shares have seen a percentage change of 0%.A block trade of $(-15.98) million in net money flow was also recorded during the day. For the block, the combined worth of upticks was $0.48 million and that of downticks was $16.46 million. The block tradeoff had the up/down ratio of 0.03.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.

Shares of Grifols, S.A. rose by 2.32% in the last five trading days and 7.09% for the last 4 weeks. Grifols, S.A. is up 21.97% in the last 3-month period. Year-to-Date the stock performance stands at 7.09%. Grifols, S.A. (NASDAQ:GRFS) rose 1.24% or 0.21 points on Wednesday and made its way into the gainers of the day. After trading began at $17.04 the stock was seen hitting $17.22 as a peak level and $16.89 as the lowest level. The stock ended up at $17.21. The daily volume was measured at 1,474,169 shares. The 52-week high of the share price is $17.4 and the 52-week low is $14.07. The company has a market cap of $11,751 million.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Grifols SA Barcelona was Upgraded by JP Morgan to Overweight on Jan 3, 2017.

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain.


Share this post

Leave a Reply